Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
Eupraxia Pharmaceuticals announced participation in several upcoming investor conferences, including Craig Hallum, BIO-Europe, Stifel, and Jefferies healthcare conferences in October and November 2026. The company will also host a virtual Analyst Day on November 13, 2026, focused on EP-104GI for eosinophilic esophagitis, which is currently in the Phase 1b/2 RESOLVE trial.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.